Skip to main content

A breakthrough alternative to antibiotics for preventing and curing infectious diseases at Intensive Care Units

Project description

Introducing a novel approach to combat antimicrobial-resistant pathogens

It is estimated that antimicrobial resistance of pathogens could become the major cause of death by 2050. Many gram-negative bacteria are especially life-threatening due to their antibiotic resistance and high presence in hospital intensive care units. The EU-funded HAIKU project aims to confirm the preclinical development process and review market conditions for RA-01, a novel drug that prevents internal bacterial infection by removing specific antibodies. This will lead to the next stage of RA-01 clinical trials, licensing and market delivery. The project will enable the prevention of infectious diseases in intensive care units, thus saving lives, reducing length of hospital stays and significantly cutting healthcare expenses.

Call for proposal


See other projects for this call

Sub call



Net EU contribution
€ 50 000,00
C Feixa Llarga Sn Edificio Biopol Office 3
08907 Hospitalet De Llobregat

See on map

Este Cataluña Barcelona
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Other funding
€ 21 429,00